Morgan Stanley raised the firm’s price target on Dyne Therapeutics to $48 from $40 and keeps an Overweight rating on the shares. Updated data for DYNE-101 and DYNE-251 were ahead of expectations and indicate continued improvements at higher doses that translate into functional benefits, further de-risking and increasing the firm’s conviction in both programs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
- Dyne Therapeutics reports Q1 EPS (81c), consensus (80c)
- Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Boeing, Paramount downgraded: Wall Street’s top analyst calls